BeStock  
Stocks › Biotechnology › PRME

Prime Medicine PRME

US equityMarket cap rank #3316Biotechnology
$3.55 −$0.29 (-7.55%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $3.56 +0.28%
Open$3.70
Prev close$3.84
Day range$3.49 – $3.94
Volume6.13M
Market cap$791.62M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$4.21M+243.9% YoY
Operating profit-$39.93M+26.0% YoY
Net profit-$39.04M+22.8% YoY
Diluted EPS-$0.22+31.3% YoY
Free cash flow-$36.98M-4.8% YoY
Operating cash flow-$36.68M

Revenue, last 8 quarters

$2.2MDec '24$1.5MMar '25$1.1MJun '25$1.2MSep '25$838.0KDec '25$856.0KMar '26$1.2MJun '26$4.2MSep '26

Net profit, last 8 quarters

$-42.3MDec '24$-51.9MMar '25$-52.6MJun '25$-50.6MSep '25$-46.1MDec '25$-49.1MMar '26$-42.1MJun '26$-39.0MSep '26

Diluted EPS by quarter

-0.31Dec '24-0.40Mar '25-0.41Jun '25-0.32Sep '25-0.24Dec '25-0.28Mar '26-0.24Jun '26-0.22Sep '26

Free cash flow by quarter

$14.5MDec '24$-51.3MMar '25$-43.0MJun '25$-35.3MSep '25$-37.5MDec '25$-42.9MMar '26$-41.1MJun '26$-37.0MSep '26

Annual revenue

$5.2MFY20$0.0FY21$0.0FY22$0.0FY23$3.0MFY24$4.6MFY25

Profitability & balance sheet

Operating margin-2,584.2%
Net margin-2,497.6%
Return on equity-207.2%
Return on assets-58.9%
Return on invested capital-90.2%
Current ratio1.79
Liabilities / assets96.1%
Cash & investments$61.16M
Total debt$101.01M
Net cash (debt)-$39.85M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $4.21M $1.15M $856,000.00 $4.63M $838,000.00
Total Operating Revenue $4.21M $1.15M $856,000.00 $4.63M $838,000.00
Operating Expense $44.14M $44.44M $51.51M $212.98M $49.45M
Selling and Admin Expenses $10.02M $11.04M $17.41M $52.35M $14.74M
-General & Admin Expense $10.02M $11.04M $17.41M $52.35M $14.74M
Research & Development $34.12M $33.40M $34.11M $160.64M $34.71M
Operating Profit -$39.93M -$43.29M -$50.65M -$208.35M -$48.61M
Net Non-Operating Interest Income (Expense) $555,000.00 $788,000.00 $1.02M $4.15M $1.08M
Non-Operating Interest Income $555,000.00 $788,000.00 $1.02M $4.15M $1.08M
Other Income (Expense) $328,000.00 $388,000.00 $511,000.00 $3.06M $1.45M
Securities Amortization -$274,000.00 -$333,000.00 -$460,000.00 -$2.48M -$858,000.00
Other Non-Operating Income (Expenses) $54,000.00 $55,000.00 $51,000.00 $148,000.00 $49,000.00
Pretax Profit -$39.04M -$42.11M -$49.12M -$201.14M -$46.08M
Net Profit -$39.04M -$42.11M -$49.12M -$201.14M -$46.08M
Profit from Continuing Operations -$39.04M -$42.11M -$49.12M -$201.14M -$46.08M
Net Income to Parent Company -$39.04M -$42.11M -$49.12M -$201.14M -$46.08M
Net Income to Common Stockholders -$39.04M -$42.11M -$49.12M -$201.14M -$46.08M
Basic EPS -$0.22 -$0.24 -$0.28 -$1.35 -$0.24
Diluted EPS -$0.22 -$0.24 -$0.28 -$1.35 -$0.24
Gain on Sale of Security – – – $432,000.00 $539,000.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $213.86M $249.04M $294.73M $342.73M $342.73M
Total Current Assets $63.69M $96.80M $137.89M $181.29M $181.29M
Cash and Cash Equivalents & Short-Term Investments $61.16M $47.45M $135.50M $177.68M $177.68M
-Cash and Cash Equivalents $54.89M $47.45M $64.11M $63.03M $63.03M
-Short Term Investments $6.27M – $71.39M $114.65M $114.65M
Other Current Assets $2.53M $95.45M $421,000.00 $674,000.00 $674,000.00
Total Non-Current Assets $150.16M $152.24M $156.84M $161.44M $161.44M
Net PPE $133.20M – $142.15M $146.75M $146.75M
-Gross PPE $159.03M – $164.44M $167.18M $167.18M
-Accumulated Depreciation -$25.83M – -$22.29M -$20.43M -$20.43M
Other Non-Current Assets $16.97M $152.24M $14.69M $14.69M $14.69M
Total Liabilities $205.42M $209.23M $218.03M $221.87M $221.87M
Total Current Liabilities $35.64M $31.69M $36.29M $37.45M $37.45M
Payables $6.40M – $12.33M $8.89M $8.89M
-Accounts Payable $6.40M $5.81M $12.33M $8.89M $8.89M
Current Accrued Expenses $4.49M $4.65M $3.76M $3.56M $3.56M
Short-Term Debt and Capital Lease Obligation $9.42M – $8.55M $8.14M $8.14M
-Current Capital Lease Obligation $9.42M $8.97M $8.55M $8.14M $8.14M
Current Deferred Liabilities $8.98M – $7.32M $7.82M $7.82M
Other Current Liabilities $1.03M $31.69M $2.15M $1.70M $1.70M
Total Non-Current Liabilities $169.78M $177.54M $181.74M $184.42M $184.42M
Long Term Debt and Capital Lease Obligation $101.01M $103.51M $105.97M $108.29M $108.29M
-Long Term Capital Lease Obligation $101.01M $103.51M $105.97M $108.29M $108.29M
Non-Current Deferred Liabilities $68.78M – $75.78M $76.13M $76.13M
Total Equity $8.44M $39.81M $76.70M $120.87M $120.87M
Stockholders' Equity $8.44M $2.00B $76.70M $120.87M $120.87M
Capital Stock $2,000.00 – $2,000.00 $2,000.00 $2,000.00
-Common Stock $2,000.00 – $2,000.00 $2,000.00 $2,000.00
Additional Paid-In Capital $1.03B $1.02B $1.01B $1.01B $1.01B
Retained Earnings -$1.02B $979.59M -$937.48M -$888.35M -$888.35M
Gains/Losses Not Affecting Retained Earnings -$3,000.00 – -$1,000.00 $82,000.00 $82,000.00
Prepaid Assets – $1.36M $1.97M $2.94M $2.94M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$36.68M -$41.05M -$42.71M -$162.56M -$37.26M
Net cash flow from continuing operations -$36.68M -$41.05M -$42.71M -$162.56M -$37.26M
Net Income from Continuing Operations -$39.04M -$42.11M -$49.12M -$201.14M -$46.08M
Depreciation & Depletion & Amortization $1.76M $1.79M $1.86M $7.32M $1.88M
Other Non-Cash Items $2.89M $2.87M $2.84M $9.70M $2.60M
Change in Working Capital -$6.89M -$8.14M -$2.50M -$5.34M $1.16M
-Change in Prepaid Assets -$3.08M $659,000.00 $1.22M $4.55M $2.60M
-Change in Payables and Accrued Expense $2.46M -$5.64M -$950,000.00 -$164,000.00 $1.02M
-Change in Other Current Liabilities -$4.02M -$69,000.00 -$1.92M -$5.36M -$1.71M
-Change In Other Working Capital -$2.25M -$3.09M -$856,000.00 -$4.36M -$751,000.00
Net cash flow from investing $41.25M $24.03M $43.39M -$108.76M $28.33M
Net Cash Flow from Continuing Investing Activities $41.25M $24.03M $43.39M -$108.76M $28.33M
Net PPE Purchase and Sale -$298,000.00 -$46,000.00 -$214,000.00 -$4.53M -$290,000.00
Net Investment Purchase and Sale $41.55M $24.08M $43.61M -$104.23M $28.62M
Financing Cash Flow $2.87M $361,000.00 $393,000.00 $151.51M $562,000.00
Net Cash Flow from Continuing Financing Activities $2.87M $361,000.00 $393,000.00 $151.51M $562,000.00
Proceeds from Stock Option Exercised $54,000.00 $361,000.00 $393,000.00 $1.12M $552,000.00
Ending Cash Balance $68.58M $61.14M $77.80M $76.72M $76.72M
Net Change in Cash $7.44M -$16.66M $1.07M -$119.82M -$8.36M
Beginning Cash Balance $61.14M $77.80M $76.72M $196.54M $85.09M
Free Cash Flow -$36.98M -$41.09M -$42.92M -$167.10M -$37.55M
-Change in Receivables – $0.00 $0.00 – –
Net Common Stock Issuance – – – $138.39M $10,000.00
Net Other Financing Charges – – – $12.00M $0.00

Discussion

No comments yet — be the first to weigh in on PRME.

Sign in to join the discussion.

Scroll to Top